Deep search
Profile Picture
  • All
  • Search
  • Copilot
  • Images
  • Videos
  • Maps
  • News
  • More
    • Shopping
    • Flights
    • Travel
    • Hotels
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
Order byBest matchMost fresh
  • Past 7 days
    • Any time
    • Past hour
    • Past 24 hours
    • Past 30 days

News

The Lancet4d
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Copyright: © 2015 Elsevier Ltd. Published by Elsevier Ltd.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Trending now

Tariffs back on for now
Feds probe impersonator
Jailed for selling daughter
Deaf Americans sue Trump
Prosecution rests its case
DOJ cuts ABA judicial vetting
Unveils new supercomputer
National Spelling Bee winner
Canada wildfires spread
Ex-NYPD commissioner dies
ICE leadership overhaul
Court declares mistrial
Saharan dust heads for FL
Brand pleads not guilty
Signs AI deal with Amazon
Paul Ingrassia to lead OSC
Garcia eyes Oversight role
Sale reaches 2,500 strikeouts
US govt. employee charged
SCOTUS narrows NEPA
To run for US Senate
On US-China trade talks
To challenge Graham
Powell meets with Trump
US scholar leaves Thailand
Foreign student ban halted
Ex-banker sentenced
Beef stew recall
MLB announces investment
Harrison Ruffin Tyler dies
SEC dismisses Binance suit
Feedback
© 2025 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices
  • Consumer Health Privacy